|
| 36215568 | <sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T Therapy. | J Nucl Med | 2023 |
| 38020530 | Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617. | Eur Urol Open Sci | 2023 |
| 37870955 | Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. | N Engl J Med | 2023 |
| 35738906 | The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). | J Nucl Med | 2023 |
| 37126544 | Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse. | Sci Adv | 2023 |
| 36990608 | Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 36988735 | Chemotherapy in Cutaneous Melanoma: Is There Still a Role? | Curr Oncol Rep | 2023 |
| 36977827 | Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress. | Br J Cancer | 2023 |
| 37439809 | Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial. | Clin Cancer Res | 2023 |
| 37404070 | Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. | J Manag Care Spec Pharm | 2023 |
| 37339186 | A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 37365284 | A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. | Br J Cancer | 2023 |
| 37199712 | Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis. | Melanoma Res | 2023 |
| 37355357 | Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6. | Eur Urol | 2023 |
| 36859685 | LXS196 for Metastatic Uveal Melanoma - finally some progress. | Br J Cancer | 2023 |
| 36872949 | Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). | Ther Adv Med Oncol | 2023 |
| 36600005 | Advances in the clinical management of uveal melanoma. | Nat Rev Clin Oncol | 2023 |
| 36860651 | Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma. | Cancer Res Commun | 2023 |
| 36222898 | Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer. | J Cancer Res Clin Oncol | 2023 |
| 36008120 | Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). | J Nucl Med | 2023 |
| 34326127 | <sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. | J Nucl Med | 2022 |
| 35510367 | A review of the cutaneous toxicities of tebentafusp-Featuring two cases involving superficial bullous reactions. | Australas J Dermatol | 2022 |
| 35643841 | Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. | Eur J Cancer | 2022 |
| 35397952 | Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. | Eur Urol | 2022 |
| 35568679 | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. | Eur J Cancer | 2022 |
| 35364234 | Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future. | Ann Oncol | 2022 |
| 35754788 | Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. | Prostate Cancer | 2022 |
| 35414591 | Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. | J Immunother Cancer | 2022 |
| 36875717 | Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. | Cancer Res Commun | 2022 |
| 36309516 | The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. | Nat Commun | 2022 |
| 36230715 | Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. | Cancers (Basel) | 2022 |
| 36261050 | PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 34973231 | Radiographic progression-free survival in the ACIS trial for prostate cancer. | Lancet Oncol | 2022 |
| 35331214 | Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. | BMC Med | 2022 |
| 34928708 | Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. | J Clin Oncol | 2022 |
| 34836681 | Patient Preference or Indifference: Learning from the CABADOC Study. | Eur Urol | 2022 |
| 34801354 | KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. | Eur J Cancer | 2022 |
| 34715287 | BRAF inhibition and the spectrum of granulomatous reactions. | J Am Acad Dermatol | 2022 |
| 32758400 | Phase I/II Trial of the Combination of <sup>177</sup>Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). | Eur Urol Oncol | 2021 |
| 35663773 | Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor. | Skin Health Dis | 2021 |
| 33682320 | UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). | BJU Int | 2021 |
| 33542074 | Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. | Clin Cancer Res | 2021 |
| 33844296 | To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma. | Cancer | 2021 |
| 33798267 | Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. | Cancer | 2021 |
| 34551229 | Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. | N Engl J Med | 2021 |
| 34638448 | Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2021 |
| 34572747 | PARP Inhibitors in Melanoma-An Expanding Therapeutic Option? | Cancers (Basel) | 2021 |
| 34571336 | Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. | Eur J Cancer | 2021 |
| 34656931 | Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. | EBioMedicine | 2021 |
| 34622543 | Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer. | BJU Int | 2021 |